-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novartis announced that its Adakveo (crizanlizumab) has been approved by the U.SFood and Drug AdministrationManagementAgency (
FDA) to reduce the frequency of pain attacks in patients with sickle cell diseaseThe drug, formerly known as SEG101, has been approved to reduce thevascularaocstatory crisis (VOC) in adult and pediatric patients 16 years of age and older with the disease's approval marks the first drug approved in the field to be treated through a combination with P-selectinP-selectors are cell-adhesive proteins that play an important role in multicellular interactions and can lead toblood vesselsocclusionapproval was based on the results of a 52-week, randomized, placebo-controlled SUSTAIN trial, which showed that Adakveo significantly reduced the median annual incidence of VOC by 1.63 to 2.98, equivalent to a 45 percent reduction compared to placebo"We know that this drug can reduce the frequency of sickle cell pain in a significant andclinicallyway," said Kenneth Ataga, director of theSickle Cell Disease Center and lead researcher on the SUSTAIN trialThe approval of Crizanlizumab is a major improvement for people with this serious disease"
sickle cell pain is triggered by multicellular interactions that form cell clusters that block or reduce the flow ofblood to the organ
